RLAY insider transaction filings
Relay Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen RLAY transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $19.74 | EDGAR |
| 2026-08-18 | 4 | Patel Sanjiv — President and CEO, Director | Sale (S): 48,199 @ $20.33 | EDGAR |
| 2026-07-30 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 2,237 @ $18.61 | EDGAR |
| 2026-07-30 | 4 | Rahmer Peter — See remarks | Sale (S): 748 @ $18.61 | EDGAR |
| 2026-07-30 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 1,459 @ $18.61 | EDGAR |
| 2026-07-08 | 4 | Patel Sanjiv — President and CEO, Director | Grant/award (A): 3,056 @ $6.95 · Sale (S): 48,199 @ $19.58 | EDGAR |
| 2026-07-08 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $18.69 | EDGAR |
| 2026-07-08 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 8,660 @ $18.71 | EDGAR |
| 2026-07-02 | 4 | Rahmer Peter — See remarks | Sale (S): 50,000 @ $19.09 · Grant/award (A): 3,056 @ $6.95 | EDGAR |
| 2026-06-24 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $17.01 · Option exercise (M): 56,323 @ $5.04 · Sale (S): 56,323 @ $16.97 · Option exercise (M): 61,563 @ $5.22 · Sale (S): 61,563 @ $16.97 · Option exercise (M): 51,560 @ $4.45 · +4 more | EDGAR |
| 2026-06-24 | 4 | Bergstrom Donald A — President, R&D | Option exercise (M): 93,456 @ $4.12 · Sale (S): 93,456 @ $16.94 · Option exercise (M): 93,456 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Mazumdar Claire — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Murcko Mark — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Dable Habib J — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | COATS LONNEL — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Borisy Alexis — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | INGRAM DOUGLAS S — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | HILL LINDA A — Director | Grant/award (A): 32,947 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $12.86 | EDGAR |
| 2026-04-30 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 972 @ $14.79 | EDGAR |
| 2026-04-30 | 4 | Rahmer Peter — See remarks | Sale (S): 753 @ $14.79 | EDGAR |
| 2026-04-30 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 1,490 @ $14.79 | EDGAR |
| 2026-04-09 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $13.01 · Option exercise (M): 1,800 @ $5.22 · Sale (S): 1,800 @ $15 · Option exercise (M): 1,800 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 17,717 @ $10.06 | EDGAR |
| 2026-01-29 | 4 | Rahmer Peter — See remarks | Grant/award (A): 994 @ $2.99 · Sale (S): 11,684 @ $7.62 · Sale (S): 1,354 @ $8.45 | EDGAR |
| 2026-01-29 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 13,820 @ $7.62 · Sale (S): 1,695 @ $8.45 | EDGAR |
| 2026-01-29 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 18,895 @ $7.62 · Sale (S): 2,686 @ $8.45 | EDGAR |
| 2026-01-15 | 4 | Rahmer Peter — See remarks | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | Patel Sanjiv — President and CEO, Director | Grant/award (A): 1,450,000 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | Catinazzo Thomas — Chief Financial Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2026-01-15 | 4 | Bergstrom Donald A — President, R&D | Grant/award (A): 575,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Patel Sanjiv — President and CEO, Director | Grant/award (A): 994 @ $2.99 · Sale (S): 43,168 @ $7.82 | EDGAR |
| 2025-11-06 | 4 | Dable Habib J — Director | Grant/award (A): 207,931 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | COATS LONNEL — Director | Grant/award (A): 207,931 (derivative) @ $0 | EDGAR |
| 2025-11-04 | 4 | Patel Sanjiv — President and CEO, Director | Sale (S): 62,073 @ $7 | EDGAR |
| 2025-10-30 | 4 | Rahmer Peter — See remarks | Sale (S): 19,135 @ $7.29 · Sale (S): 21,394 @ $7.50 | EDGAR |
| 2025-10-30 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 21,664 @ $7.29 | EDGAR |
| 2025-10-30 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 30,897 @ $7.29 | EDGAR |
| 2025-07-30 | 4 | Rahmer Peter — See remarks | Sale (S): 1,359 @ $3.74 · Sale (S): 15,724 @ $3.68 | EDGAR |
| 2025-07-30 | 4 | Catinazzo Thomas — Chief Financial Officer | Sale (S): 1,701 @ $3.74 · Sale (S): 18,380 @ $3.68 | EDGAR |
| 2025-07-30 | 4 | Bergstrom Donald A — President, R&D | Sale (S): 4,069 @ $3.74 · Sale (S): 26,701 @ $3.68 | EDGAR |
| 2025-07-30 | 4 | Adams Brian — Chief Legal Officer | Sale (S): 1,637 @ $3.74 · Sale (S): 18,276 @ $3.68 | EDGAR |
| 2025-07-10 | 4 | Patel Sanjiv — President and CEO, Director | Sale (S): 42,740 @ $3.57 · Sale (S): 18,639 @ $3.57 | EDGAR |
| 2025-07-01 | 4 | Rahmer Peter — See remarks | Grant/award (A): 5,000 @ $2.94 | EDGAR |
| 2025-07-01 | 4 | Patel Sanjiv — President and CEO, Director | Grant/award (A): 5,000 @ $2.94 | EDGAR |
| 2025-06-11 | 4 | Mazumdar Claire — Director | Grant/award (A): 421,241 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kathiresan Sekar — Director | Grant/award (A): 136,681 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Murcko Mark — Director | Grant/award (A): 136,681 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Rubin Jami — Director | Grant/award (A): 136,681 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Borisy Alexis — Director | Grant/award (A): 136,681 (derivative) @ $0 | EDGAR |
Recent 8-K events — Relay Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-11 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RLAY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →